Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics outlined a manufacturing-first strategy for COR1 , its preclinical corneal endothelial cell therapy, emphasizing scale, storage, quality and consistency before entering clinical trials. The company says COR1 is being developed as a frozen “Thaw and Inject” product that could improve access versus cadaver-derived cells, with a two-tier cell banking system and cryopreservation designed for repeatable large-scale production. Management said the eventual procedure could be a minimally invasive outpatient injection into the eye’s anterior chamber, potentially requiring only short-term immunosuppression and offering a simpler, lower-cost alternative to current corneal transplant methods. Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease. Chief Executive Officer Brian Culley said the company held the standalone call because cell transplant manufacturing outside oncology is an emerging area of regenerative medicine and because Lineage wants investors to understand how its experience with OpRegen may apply to internally owned pipeline programs. COR1 is designed to produce corneal endothelial cells, or CEnCs, from a self-renewing pluripotent cell line. Culley said the company is focused on four attributes for the program: scale, storage, quality and consistency. Lineage Emphasizes Manufacturing Before Clinical Testing Culley contrasted Lineage’s approach with small-molecule and gene therapy development, saying cell therapy products are highly dependent on the processe...